IGF-1 LR3 // Growth Factor
Modified IGF-1 with a dramatically extended half-life. The LR3 modification reduces binding protein interference, increasing bioavailability 2–3x over native IGF-1. The most potent growth factor for muscle development — and the only compound that may drive true muscle fiber hyperplasia (new fibers, not just bigger ones) in humans.
The most potent growth signal available.
IGF-1 is the primary mediator of GH's anabolic effects. The LR3 modification extends its half-life from minutes to 20-30 hours and reduces binding protein sequestration. This means more IGF-1 reaches muscle tissue for longer — driving protein synthesis, satellite cell activation, and potentially new muscle fiber formation.
Daily, post-workout or bilateral injection.
IGF-1 LR3 can be injected subcutaneously (systemic) or intramuscularly into target muscles (localized growth signal). Post-workout timing capitalizes on the anabolic window. Start conservative — the potency is significant.
From GH mediator to standalone growth factor.
IGF-1 (Insulin-like Growth Factor 1) is produced primarily in the liver in response to GH stimulation. It mediates most of GH's anabolic effects — muscle growth, bone density, and tissue repair. Recombinant IGF-1 (mecasermin/Increlex) is FDA-approved for IGF-1 deficiency.
The LR3 modification was developed to overcome the limitations of native IGF-1: extremely short half-life (~15 minutes) and extensive binding protein sequestration (98%+ bound). LR3 extends half-life to 20-30 hours and reduces binding, dramatically increasing bioactive IGF-1.
The hyperplasia question remains the most debated topic in performance peptides. Animal data suggests IGF-1 can activate satellite cells to form new muscle fibers — not just enlarge existing ones. Whether this occurs in adult humans at achievable doses is unconfirmed but represents IGF-1 LR3's unique theoretical advantage.
Growth factor comparison.
| Compound | Half-Life | Mechanism | Hyperplasia | Status |
|---|---|---|---|---|
| IGF-1 LR3 | 20–30 hours | Direct IGF-1R | Theoretical | Research |
| Native IGF-1 | ~15 minutes | Direct IGF-1R | Limited | FDA (deficiency) |
| MGF (PEG) | ~Days | Satellite Cell | Theoretical | Research |
| GH Secretagogues | Indirect | Via liver IGF-1 | No | Research |
What to watch for.
IGF-1 LR3's side effect profile is manageable with proper protocol adherence. Baseline blood work before starting and periodic monitoring during use is essential.
- Hypoglycemia (IGF-1 lowers blood glucose — have carbs available)
- Joint pain / water retention
- Gut growth at high doses (IGF-1 grows all tissue)
- Theoretical cancer acceleration (IGF-1 promotes cell proliferation)
- Tingling / numbness (transient)
- WADA banned
- Do not exceed 6-week cycles
- IGF-1 levels (monitor elevation)
- Fasting glucose and insulin (hypoglycemia risk)
- HbA1c
- Cancer screening (comprehensive — IGF-1 promotes cell growth)
- Liver enzymes
- Complete blood count
- Comprehensive metabolic panel
- Follistatin 344 for myostatin inhibition + growth factor (Performance Stack)
- CJC-1295/Ipamorelin for GH foundation
- BPC-157/TB-500 for recovery during aggressive growth
- Always have fast carbs available (hypoglycemia risk)
- WADA banned — not for tested athletes
- Cancer screening before starting — IGF-1 promotes ALL cell growth
- Maximum 6-week cycles with 4+ weeks off
- Lyophilized: store at -20°C for long-term
- Short-term: refrigerate at 2–8°C
- Reconstituted: refrigerate, use within 14 days
- Protect from light
- Sensitive to agitation — do not shake
Compounds that complement IGF-1 LR3.
The most potent anabolic peptide — and the one that demands the most respect.
IGF-1 LR3 is the strongest growth signal you can inject. The 20-30 hour half-life and reduced binding protein interference means sustained, bioactive IGF-1 reaching muscle tissue far beyond what GH secretagogues can achieve indirectly. The theoretical hyperplasia potential is unique — no other compound can claim new muscle fiber formation. But potency demands caution: hypoglycemia is real (carry carbs), IGF-1 grows ALL tissue (including potentially cancerous cells), and the long-term safety data is minimal. Cancer screening before starting, glucose monitoring during, and strict 6-week cycle limits. Stack with Follistatin for the full Performance Stack. This is the deep end — advanced users with medical supervision only.
Our free Protocol Guide includes the Performance Stack — IGF-1 LR3, Follistatin, blood work panels, and advanced protocol safety guidelines.